New insights into the pharmacodynamic and pharmacokinetic properties of statins.
about
Statins for primary prevention of venous thromboembolismStatins for primary prevention of venous thromboembolismStatins for prevention of venous thromboembolismPleiotropic effects of statinsThe bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizonsManagement of intracerebral hemorrhage--use of statinsRepurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD?Pediatric Statin Administration: Navigating a Frontier with Limited DataRhabdomyolysis with concurrent atorvastatin and diltiazemHMG-CoA reductase inhibitors and P-glycoprotein modulationThe effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptorNK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cellsCholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort studyPitavastatin and carbohydrate metabolism: what is the evidence?Statins, bugs and prophylaxis: intriguing possibilities.Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.Orally administered simvastatin partially preserves lumbar vertebral bone mass but not integrity of intervertebral discs in ovariectomized rats.POSSIBLE REGULATION OF LDL-RECEPTOR BY NARINGENIN IN HEPG2 HEPATOMA CELL LINE.Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase InhibitorsStatins impair CD1d-mediated antigen presentation through the inhibition of prenylation.Preadmission statin use and one-year mortality among patients in intensive care - a cohort study.Non-lipid-related effects of statins.Statins and their interactions with other lipid-modifying medications: safety issues in the elderlySimvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR.Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis.Fluvastatin: effects beyond cholesterol lowering.Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.Statins and myocardial remodelling: cell and molecular pathways.Atorvastatin.The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.Statin use and risk of pancreatic cancer: a meta-analysis.Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage.Statin drug interactions and related adverse reactions.Rhabdomyolysis and HMG-CoA reductase inhibitors.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Statins and selective inhibition of Rho kinase protect small conductance calcium-activated potassium channel function (K(Ca)2.3) in cerebral arteries.
P2860
Q24187238-D8935193-3E80-4EA6-A943-E211F1B01624Q24204040-9D806858-067D-41CF-B1AE-C334814A1311Q24241510-C8DB03C4-DADA-4875-AADA-D18D212CAA4CQ24647863-15EBBD22-E95A-4093-AE03-A7EDF12820EEQ24684244-67C20502-D7BD-42D8-A8E1-751C16AA4C75Q26752168-4B576A7D-C8ED-4285-BCE1-202942612F8AQ26752952-E42F7D10-1046-4503-A4FB-F9319038A1F5Q28066773-49ED9EED-45FE-4BC3-AE00-73F8B15CAD24Q28068014-46A547B5-30CC-47E1-9105-5FAE2AF4FD8CQ28193807-94902C7A-A926-4CE2-9DD8-00D50D0BDC51Q28360140-E726FF5A-4AF7-4A72-BC3A-A278C268A40AQ28363003-6E797B87-4783-45DD-BF19-4348FB347CB3Q28363802-6315226E-9D32-41AB-912B-847D0C669D6FQ28740349-4046FBDC-D231-4D68-92F9-7F8D5D0C277BQ30251801-E411E3AF-1A8A-4122-BFFF-058D74BBDA92Q30357923-561C4487-4CE6-4E5A-B706-1F4A8C45E282Q31989536-9A03CCB0-E906-4D9A-A162-719E607ECFB5Q33585657-8A471A92-E3A5-48EC-BE59-5D389607D8F0Q33599000-FB0684AC-4B9F-43C4-8A6C-AE3B39C9B6A4Q33623018-ABB427BF-8DA7-4CC1-93CA-5D4ED1C5A931Q33763342-6A5DC564-CBD4-453A-8FE6-219F5C53298CQ33773451-70878659-4DF8-4A1D-9F8B-DC87229C4CCDQ33919029-CB29893A-D160-4827-B8CB-7721CE4189D1Q33924588-F784463C-5B31-4242-8DE8-26B289E40BC4Q33949348-5A8B2ED2-6446-48D3-8F4C-5A84D275EA1AQ33976397-8D427F98-8997-473A-93F0-1F97B66C9F81Q33995617-3E936E5F-7C42-4569-8E48-1BC476DFBADFQ34019282-03BF7728-70B8-48D5-9264-08A4E22EC1CBQ34101296-96361DC7-C82E-4230-B0CD-17F951D838DBQ34126048-46A24281-7689-4B54-9A7C-2BA046CD65AFQ34182077-0A5B6CCC-24E6-4826-9C60-DD5CD0B019E2Q34196628-96117414-AC16-472A-9F91-4AA44F8BA594Q34241040-60FD9F23-F5AA-4B9E-9F94-B6558E22225AQ34258208-68F3F455-BFA2-4D65-97BC-23DC5EF0ACF0Q34273115-620E865C-9D04-4225-B649-7EE310411D0DQ34276487-663F5056-6E1E-49EA-8FE8-62BEF7A4D1A3Q34292468-9010E7D1-DC2B-450D-841D-CEBEA4315153Q34382555-D8F3A2DF-5C85-4ED3-B5A5-CD4BC93CE6F3Q34429685-E18CBE04-952B-4EF2-911E-82D60B2DE32AQ34442012-975BBDAE-2DB2-4F5B-93BC-46C91D0A4BE9
P2860
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@ast
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@en
type
label
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@ast
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@en
prefLabel
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@ast
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
@en
P2093
P1476
New insights into the pharmacodynamic and pharmacokinetic properties of statins
@en
P2093
R Fumagalli
R Paoletti
S Bellosta
P304
P356
10.1016/S0163-7258(99)00045-5
P577
1999-12-01T00:00:00Z